RGEN — REPLIGEN CORP
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 730272 ·
Last close
$115.19
Market Cap
$6.50B
52W High
$141.46
52W Low
$100.99
ADV30
1,280,493
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 197,913,000 | 103,831,000 | 16,348,000 | 13,287,000 | 2,949,699,000 | 566,021,000 | 843,570,000 |
| Sep 2025 | 188,805,000 | 100,515,000 | 12,677,000 | 14,911,000 | 2,923,711,000 | 748,747,000 | 840,624,000 |
| Jun 2025 | 182,366,000 | 91,142,000 | 5,957,000 | 14,866,000 | 2,901,627,000 | 708,855,000 | 839,886,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$117,417,000
Investing CF
$-298,474,000
Financing CF
$-15,205,000
CapEx
$-25,730,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$456,248,000
Inventory
$170,458,000
Receivables
$158,587,000
ST Investments
$201,607,000
EBIT TTM
$70,703,000
Pretax Income TTM
$54,440,000
Interest Exp TTM
$16,263,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$763,339,008
EBITDA
$134,236,992
Free Cash Flow
$68,723,376
Enterprise Value
$6,393,363,456
Total Cash
$784,531,008
Total Debt
$687,619,968
Shares Out
56,407,740
Trailing EPS
$0.91
Book Value
$37.33
ROE
2.5%
ROA
1.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 738,256,000 | 41,560,000 | 48,894,000 | 2,949,699,000 | 843,570,000 | — | 117,417,000 |
| Dec 2024 | 634,439,000 | -31,923,000 | -25,514,000 | 2,829,666,000 | 856,948,000 | — | 175,394,000 |
| Dec 2023 | 632,362,000 | 17,134,000 | 35,596,000 | 2,831,185,000 | 866,340,000 | — | 113,918,000 |
| Dec 2022 | 801,536,000 | 195,941,000 | 185,959,000 | 2,531,600,000 | 620,900,000 | — | 172,083,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | $6.64B | $80.77 | — |
| SRRK | Scholar Rock Holding Corp | $6.17B | $51.51 | — |
| IMVT | Immunovant, Inc. | $6.95B | $33.83 | — |
| PCVX | Vaxcyte, Inc. | $7.24B | $50.11 | — |
| QGEN | QIAGEN N.V. | $7.33B | $35.54 | — |
News headlines (Yahoo Finance, 1h cache)
3 Out-of-Favor Stocks We Keep Off Our Radar
2026-05-23 09:24 · Yahoo
3 Stocks That May Be Trading Below Their Estimated Value In May 2026
2026-05-22 11:38 · Yahoo
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
2026-05-22 11:30 · Yahoo
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
2026-05-20 23:24 · Yahoo
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
2026-05-20 11:30 · Yahoo
Why Repligen (RGEN) Stock Is Trading Up Today
2026-05-19 15:00 · Yahoo
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
2026-05-19 12:28 · Yahoo
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
2026-05-17 09:56 · Yahoo
3 Small-Cap Stocks We Steer Clear Of
2026-05-15 13:08 · Yahoo
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call
2026-05-15 09:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.